Report cover image

Advanced Therapy Medicinal Products CDMO Market by Products (Cell Therapy, Gene Therapy, Tissue Engineered), Phase (Phase I, Phase II, Phase III), Indication, End-Users - Global Forecast 2024-2030

Publisher 360iResearch
Published Jan 15, 2024
Length 186 Pages
SKU # IRE18417931

Description

Advanced Therapy Medicinal Products CDMO Market by Products (Cell Therapy, Gene Therapy, Tissue Engineered), Phase (Phase I, Phase II, Phase III), Indication, End-Users - Global Forecast 2024-2030


The Advanced Therapy Medicinal Products CDMO Market size was estimated at USD 7.54 billion in 2023 and expected to reach USD 8.74 billion in 2024, at a CAGR 17.06% to reach USD 22.74 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Advanced Therapy Medicinal Products CDMO Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Advanced Therapy Medicinal Products CDMO Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Advanced Therapy Medicinal Products CDMO Market, highlighting leading vendors and their innovative profiles. These include Abzena, Advanced Therapies, Inc. by WuXi AppTec, AGC Inc., Aldevron, Almac Group, Arranta Bio Holdings, LLC, Bio Elpida, BlueReg, Catalent Inc., CELONIC Group, CGT Catapult, Charles River Laboratories International, Inc., Coriolis Pharma Research GmbH, Eurofins Scientific SE, FUJIFILM Corporation, Lonza Group, Minaris Regenerative Medicine, Oxford Biomedica PLC, Patheon by Thermo Fisher Scientific Inc., Rentschler Biopharma SE, REPROCELL Inc., RoslinCT, Samsung Biologics, and VIVEBIOTECH S.L..

Market Segmentation & Coverage

This research report categorizes the Advanced Therapy Medicinal Products CDMO Market to forecast the revenues and analyze trends in each of the following sub-markets:

Products

Cell Therapy
  • Gene Therapy
  • Tissue Engineered
  • Phase

    Phase I
  • Phase II
  • Phase III
  • Phase IV
  • Indication

    Cardiology
  • Central Nervous System
  • Dermatology
  • Endocrine, Metabolic, Genetic
  • Gastroenterology
  • Hematology
  • Immunology & Inflammation
  • Infectious Disease
  • Musculoskeletal
  • Oncology
  • Ophthalmology
  • End-Users

    Academic and Research Institutions
  • Biotechnology & Pharmaceutical Companies
  • Clinical Research Organizations (CROs)
  • Hospitals and Clinics
  • Region

    Americas

    Argentina
  • Brazil
  • Canada
  • Mexico
  • United States

    California
  • Florida
  • Illinois
  • New York
  • Ohio
  • Pennsylvania
  • Texas
  • Asia-Pacific

    Australia
  • China
  • India
  • Indonesia
  • Japan
  • Malaysia
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
  • Vietnam
  • Europe, Middle East & Africa

    Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom
    The report offers valuable insights on the following aspects:

    1. Market Penetration: It presents comprehensive information on the market provided by key players.
    2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
    3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
    4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
    5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
    The report addresses key questions such as:

    1. What is the market size and forecast of the Advanced Therapy Medicinal Products CDMO Market?
    2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Advanced Therapy Medicinal Products CDMO Market?
    3. What are the technology trends and regulatory frameworks in the Advanced Therapy Medicinal Products CDMO Market?
    4. What is the market share of the leading vendors in the Advanced Therapy Medicinal Products CDMO Market?
    5. Which modes and strategic moves are suitable for entering the Advanced Therapy Medicinal Products CDMO Market?


    Note: PDF & Excel + Online Access - 1 Year

    • Table of Contents

    186 Pages
    1. Preface
    1.1. Objectives of the Study
    1.2. Market Segmentation & Coverage
    1.3. Years Considered for the Study
    1.4. Currency & Pricing
    1.5. Language
    1.6. Limitations
    1.7. Assumptions
    1.8. Stakeholders
    2. Research Methodology
    2.1. Define: Research Objective
    2.2. Determine: Research Design
    2.3. Prepare: Research Instrument
    2.4. Collect: Data Source
    2.5. Analyze: Data Interpretation
    2.6. Formulate: Data Verification
    2.7. Publish: Research Report
    2.8. Repeat: Report Update
    3. Executive Summary
    4. Market Overview
    4.1. Introduction
    4.2. Advanced Therapy Medicinal Products CDMO Market, by Region
    5. Market Insights
    5.1. Market Dynamics
    5.1.1. Drivers
    5.1.1.1. Proliferation in prevalence of rare diseases with growing emergence of novel
    infectious diseases
    5.1.1.2. Rising numbers of clinical trials for development of advanced therapy medicinal products
    5.1.1.3. Increasing investments in pharmaceutical research and development worldwide
    5.1.2. Restraints
    5.1.2.1. High cost associated with outsourcing ATMP solutions
    5.1.3. Opportunities
    5.1.3.1. Adoption of advanced technologies by advanced therapy medicinal
    products CDMOs
    5.1.3.2. Strategic alliance and expansion activities for R&D of advanced therapy medicinal products
    5.1.4. Challenges
    5.1.4.1. Stringent governmental rules and regulations for ATMP approvals and
    commercialization
    5.2. Market Segmentation Analysis
    5.3. Market Trend Analysis
    5.4. Cumulative Impact of High Inflation
    5.5. Porter’s Five Forces Analysis
    5.5.1. Threat of New Entrants
    5.5.2. Threat of Substitutes
    5.5.3. Bargaining Power of Customers
    5.5.4. Bargaining Power of Suppliers
    5.5.5. Industry Rivalry
    5.6. Value Chain & Critical Path Analysis
    5.7. Regulatory Framework
    6. Advanced Therapy Medicinal Products CDMO Market, by Products
    6.1. Introduction
    6.2. Cell Therapy
    6.3. Gene Therapy
    6.4. Tissue Engineered
    7. Advanced Therapy Medicinal Products CDMO Market, by Phase
    7.1. Introduction
    7.2. Phase I
    7.3. Phase II
    7.4. Phase III
    7.5. Phase IV
    8. Advanced Therapy Medicinal Products CDMO Market, by Indication
    8.1. Introduction
    8.2. Cardiology
    8.3. Central Nervous System
    8.4. Dermatology
    8.5. Endocrine, Metabolic, Genetic
    8.6. Gastroenterology
    8.7. Hematology
    8.8. Immunology & Inflammation
    8.9. Infectious Disease
    8.10. Musculoskeletal
    8.11. Oncology
    8.12. Ophthalmology
    9. Advanced Therapy Medicinal Products CDMO Market, by End-Users
    9.1. Introduction
    9.2. Academic and Research Institutions
    9.3. Biotechnology & Pharmaceutical Companies
    9.4. Clinical Research Organizations (CROs)
    9.5. Hospitals and Clinics
    10. Americas Advanced Therapy Medicinal Products CDMO Market
    10.1. Introduction
    10.2. Argentina
    10.3. Brazil
    10.4. Canada
    10.5. Mexico
    10.6. United States
    11. Asia-Pacific Advanced Therapy Medicinal Products CDMO Market
    11.1. Introduction
    11.2. Australia
    11.3. China
    11.4. India
    11.5. Indonesia
    11.6. Japan
    11.7. Malaysia
    11.8. Philippines
    11.9. Singapore
    11.10. South Korea
    11.11. Taiwan
    11.12. Thailand
    11.13. Vietnam
    12. Europe, Middle East & Africa Advanced Therapy Medicinal Products CDMO Market
    12.1. Introduction
    12.2. Denmark
    12.3. Egypt
    12.4. Finland
    12.5. France
    12.6. Germany
    12.7. Israel
    12.8. Italy
    12.9. Netherlands
    12.10. Nigeria
    12.11. Norway
    12.12. Poland
    12.13. Qatar
    12.14. Russia
    12.15. Saudi Arabia
    12.16. South Africa
    12.17. Spain
    12.18. Sweden
    12.19. Switzerland
    12.20. Turkey
    12.21. United Arab Emirates
    12.22. United Kingdom
    13. Competitive Landscape
    13.1. FPNV Positioning Matrix
    13.2. Market Share Analysis, By Key Player
    13.3. Competitive Scenario Analysis, By Key Player
    14. Competitive Portfolio
    14.1. Key Company Profiles
    14.1.1. Abzena
    14.1.2. Advanced Therapies, Inc. by WuXi AppTec
    14.1.3. AGC Inc.
    14.1.4. Aldevron
    14.1.5. Almac Group
    14.1.6. Arranta Bio Holdings, LLC
    14.1.7. Bio Elpida
    14.1.8. BlueReg
    14.1.9. Catalent Inc.
    14.1.10. CELONIC Group
    14.1.11. CGT Catapult
    14.1.12. Charles River Laboratories International, Inc.
    14.1.13. Coriolis Pharma Research GmbH
    14.1.14. Eurofins Scientific SE
    14.1.15. FUJIFILM Corporation
    14.1.16. Lonza Group
    14.1.17. Minaris Regenerative Medicine
    14.1.18. Oxford Biomedica PLC
    14.1.19. Patheon by Thermo Fisher Scientific Inc.
    14.1.20. Rentschler Biopharma SE
    14.1.21. REPROCELL Inc.
    14.1.22. RoslinCT
    14.1.23. Samsung Biologics
    14.1.24. VIVEBIOTECH S.L.
    14.2. Key Product Portfolio
    15. Appendix
    15.1. Discussion Guide
    15.2. License & Pricing
    FIGURE 1. ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET RESEARCH PROCESS
    FIGURE 2. ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2023 VS 2030
    FIGURE 3. ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2030 (USD MILLION)
    FIGURE 4. ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY REGION, 2023 VS 2030 (%)
    FIGURE 5. ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 6. ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET DYNAMICS
    FIGURE 7. ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2023 VS 2030 (%)
    FIGURE 8. ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 9. ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2023 VS 2030 (%)
    FIGURE 10. ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 11. ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
    FIGURE 12. ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 13. ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
    FIGURE 14. ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 15. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 16. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 17. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY STATE, 2023 VS 2030 (%)
    FIGURE 18. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 19. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 20. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 23. ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, FPNV POSITIONING MATRIX, 2023
    FIGURE 24. ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SHARE, BY KEY PLAYER, 2023

    Pricing

    Currency Rates
    How Do Licenses Work?

    How Do Licenses Work?

    The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

    • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

    • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

    • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

    • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

    • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

    License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

    Head shot

    Questions or Comments?

    Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
    Chat Now
    Contact Us